Einladung Webinar: Ultrarapid RNA-based Gene fusion detection in under 3 hours - ALK, ROS1, RET, NTRK1/2/3 Rearrangements and MET Exon 14 Skipping
Register via Registration (gotowebinar.com)
When: Wed, Jun 29, 2022 7:00 PM - 7:45 PM CEST
Presenter: Maria E. Arcila, MD
Laboratory Director, Diagnostic Molecular Pathology Laboratory
Memorial Sloan Kettering Cancer Center
? Therapeutically actionable gene fusions drive approximately 10% of non-small-cell lung cancers.*
? Current molecular methods including Next Generation Sequencing (NGS) are complex with long turnaround times.
? Learn how the Idylla? GeneFusion Assay (RUO)** enables more rapid screening of targetable fusions compared to routine methods.
*Lee SE, et al., ‘Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma’ Mod Pathol 2015, 28:468e479; and Pan Y et al., ‘ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features’, Lung Cancer 2014, 84:121e126
**Research Use Only, not for use in diagnostic procedures